Treating
Neurodegenerative Disease
by Restoring Autophagy

Samsara Therapeutics

Our Mission

Samsara Therapeutics: Treating Neurodegeneration by Improving Autophagy

At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families.

get in touch
Our Foundation

Founded in 2019 and operating from our corporate headquarters in Boston and our R&D hub in Oxford

Samsara has emerged as a leader in the pursuit of therapeutics for neurodegenerative diseases via the autophagy activation domain. In 2021, Apollo Health Ventures led our $25M Series A given their dedication to investing in companies that pursue innovative approaches to treating age-related diseases.

Based on the scientific achievements driven from our pipeline, Samsara has collected additional endorsement and funding from patient advocacy organizations including

We are committed to providing new opportunities for patients and their families through our drug discovery and development efforts.

Pipeline
Our Leadership

Our senior leadership team

is comprised by a diverse group of seasoned experts who bring a proven track record in pharmaceutical and biotechnological innovation.

about us
Our Portfolio

Innovative Programs Targeting Neurodegeneration

Our portfolio encompasses multiple programs, each designed to tackle various indications of neurodegenerative diseases through autophagy activation:

SAM001 for ALS

leveraging lysosomal biogenesis to delay disease progression

SAM0021 for PD and SAM0022 for CMT

focusing on autophagosome formation

SAM005 for CMT

aiming at phagophore recruitment

In House Discovery Platform

driving high-throughput, cell-based screening for small molecule autophagy activators in disease relevant, patient derived iPSCs

Our Platform

Phenotypic Screening Platform for Autophagy Related Diseases in Patient Derived Cells

The core of our discovery process is to screen and identify potential autophagy activators,  which are then validated in our in house, disease-relevant iPSC (Induced Pluripotent Stem Cells) core across different disease pathologies and patient genotypes. This comprehensive approach enables the efficient advancement of the most promising compounds towards preclinical and clinical development.

Science Oxford Centre
Quarry Road, Headington
Oxford, OX3 8SB​
UK

50 Milk Street​
Boston​
MA 02108​
USA
Contact

Privacy policy

Designed by HensOnMars for Samsara Therapeutics © 2024